Approval Background and Product Composition

The European Medicines Agency (EMA) approved GSK's (GSK) Trelegy Ellipta, a triple-combination therapy for chronic obstructive pulmonary disease (COPD), on November 15, 2017. This therapy combines fluticasone furoate (a corticosteroid, or glucocorticoid receptor agonist), umeclidinium (a long-acting muscarinic antagonist, or LAMA, and an M3 muscarinic receptor antagonist), and vilanterol (a long-acting beta2-agonist, or LABA, and a beta2-adrenergic receptor agonist) into a single inhaler. The approval was based on the IMPACT and FULFIL Phase 3 clinical trials, which demonstrated superior improvements in lung function and a reduction in the rate of acute exacerbations compared to existing dual therapies.

Clinical Data and Competitive Advantages

The pivotal Phase 3 IMPACT trial for Trelegy Ellipta involved 10,355 patients with moderate-to-very severe COPD over 52 weeks. The results showed that Trelegy Ellipta significantly reduced the rate of moderate and severe acute exacerbations by 15% and 25%, respectively, compared to the dual combination therapies Relvar Ellipta (ICS/LABA) and Anoro Ellipta (LAMA/LABA). The FULFIL Phase 3 trial also demonstrated statistically significant improvements in lung function (FEV1) and patient-reported outcomes (SGRQ) compared to Symbicort (budesonide/formoterol), establishing its pharmacological superiority.

Market Size and Competitive Positioning

The global COPD treatment market is estimated at approximately $13.1 billion to $22.1 billion in 2024, with the triple-combination segment driving growth. Trelegy Ellipta is a blockbuster drug, generating global sales of approximately £2.2 billion (approximately $2.8 billion) in 2023. Its main competitor is Breztri Aerosphere (budesonide/glycopyrronium/formoterol) from AstraZeneca (AZN). As a first-in-class triple combination therapy, Trelegy Ellipta has established a strong market share and continues to maintain a leading position in the European market.

Partnerships and Deal Structure

Trelegy Ellipta was developed through a long-term respiratory collaboration between GSK, Innoviva (INVA), and Theravance BioPharma (TBPH). Innoviva and Theravance originally received a percentage of the net sales of Trelegy Ellipta. However, in July 2022, they entered into a major deal to sell these royalty rights to Royalty Pharma (RPRX) in exchange for an upfront payment. Subsequently, in June 2025, Theravance sold its remaining royalty rights to GSK, further simplifying the deal structure.

Long-Term Industry Impact

The EMA approval of Trelegy Ellipta has accelerated the shift in COPD treatment paradigms from dual to triple combination therapies. By maximizing the convenience of a single-inhaler regimen, it has improved patient adherence, leading to overall healthcare cost savings and improved patient outcomes. With the potential for future approval for asthma, its impact on the European respiratory market is expected to expand further in the long term.